Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030

Table 2 Antiviral agents for hepatitis B infection in children[44]

Medication	Licensing	Dose and duration	HBsAg loss (%)	Resistance (%)
IFN-α-2b	≥ 1 yr	6 million IU/m2 three times weekly for 6 mo	1-2	0
Lamivudine	≥ 2 yr	3 mg/kg daily for ≥ 1 yr	0	19-64
Entecavir	≥ 2 yr	0.25-0.5 mg daily for ≥ 1 yr	0.52	0.7-1.2
Tenofovir dipovaxil fumarate	≥ 12 yr	300 mg daily for ≥ 1 yr	0.02	0
Adefovir	≥ 12 yr	10 mg daily for ≥ 1 yr	0	0.9-20

HBsAg: Hepatitis B surface antigen.